中新藥業(600329.SH):公司A股證券簡稱自5月26日起變更為“達仁堂”
格隆匯5月19日丨中新藥業(600329.SH)公佈,根據相關法律法規及《公司章程》的規定,公司向天津市市場監督管理委員會申請辦理工商變更登記手續,並於2022年5月18日辦理完畢,取得了天津市市場監督管理委員會換髮的《營業執照》。鑑於公司名稱現已變更為“津藥達仁堂集團股份有限公司”,經公司申請,並經上海證券交易所辦理,公司A股證券簡稱自2022年5月26日起,由“中新藥業”變更為“達仁堂”,公司A股證券代碼“600329”保持不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.